A Safety and Pharmacokinetics Trial of IDP-122 Lotion in Children With Psoriasis
Phase 4
45
about 6.7 years
6–17
7 sites in CA, FL, SC +1
What this study is about
This trial is testing the safety, how much of halobetasol propionate (HP) is absorbed into the body, and if it affects the HPA axis for topically applied IDP-122 lotion in children with moderate to severe plaque psoriasis. The treatment will be applied topically.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IDP-122 Lotion
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
topical
Primary: Pharmacokinetics: Maximum Observed Drug (Halobetasol Propionate) Concentration in Plasma (Cmax) of IDP-122 Lotion Analytes
Dermatology